Cytori Cell Research Institute, Inc. (3750) AI Stock Analysis

• Market Cap: ¥8.16B
• Dividend Yield: N/A
• Average Volume (3M): 9.66K
• Price to Earnings (P/E): 55.1
• Beta (1Y): 0.47
• Revenue Growth: -92.12%
• EPS Growth: -3310.68%
• Country: JP
• Employees: 16
• Sector: Healthcare
• Sector Strength: 51
• Industry: Biotechnology
• EPS (TTM): 7.82
• Shares Outstanding: 8,929,419
• 10 Day Avg. Volume: 3,130
• 30 Day Avg. Volume: 9,656
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥827.00
• Price Target Upside: -9.52% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 54 Neutral
• Price Target: ¥827.00 ▼(-9.52% Downside)

Cytori Cell Research Institute's score is primarily driven by its weak financial performance, reflecting significant profitability and liquidity challenges, along with a concerning valuation due to negative earnings. Despite these issues, the stock's strong technical indicators suggest short-term bullish momentum, which partially offsets the financial weaknesses. The absence of earnings call insights and corporate events further underscores the need for financial improvement.

Cytori Cell Research Institute, Inc. Business Overview & Revenue Model

Company Description

Cytori Cell Research Institute, Inc., engages in the research, development, production, and sale of cell therapy related medical devices in Japan. The company sells cell therapy kits, as well as engages in the research and development of cell therapy technology, etc. Its products pipeline includes ECCI-50 for the treatment of male stress urinary incontinence and liver cirrhosis; and Cyt-006 to prevent postoperative adhesion for primary rectal cancer. The company is also conducting clinical trials/research on cell therapy for a range of diseases and applications, including anterior cruciate ligament repair, bone repair, burn scars, chronic wound healing, critical limb ischemia, anal and Crohn's disease fistulas, erectile dysfunction, etc. It also invests in, owns, develops, leases, and manages real estate projects and hotels; and provides real estate brokerage services. The company was formerly known as FRACTALE Corporation. Cytori Cell Research Institute, Inc. was incorporated in 2004 and is headquartered in Tokyo, Japan.

How the Company Makes Money

Cytori Cell Research Institute, Inc. generates revenue primarily through the development and commercialization of its proprietary cell-based therapies. The company earns income by selling its regenerative medicine products and licensing its technology to other biotechnology and pharmaceutical companies. Additionally, it may engage in strategic partnerships and collaborations with research institutions or healthcare providers to expand its market reach and enhance its product offerings. Revenue streams can also include grants and funding from government or private entities supporting scientific research and development in regenerative medicine.

Cytori Cell Research Institute, Inc. Financial Statement Overview

Summary

Cytori Cell Research Institute faces significant financial challenges. The income statement shows declining revenues and increasing losses, compounded by high financial leverage and negative cash flow from operations. These factors indicate a high financial risk and necessitate strategic revenue stabilization and cost management.

Income Statement

Cytori Cell Research Institute's income statement reveals significant challenges, as evidenced by declining revenue and profitability. The revenue has decreased considerably from previous years, and the gross profit has turned negative, indicating increased cost pressures. The net profit margin and EBIT margin are both negative, reflecting persistent losses. The revenue growth rate has been negative for the latest period, showing a decline in sales. These factors contribute to a low score, highlighting the need for revenue stabilization and cost management strategies.

Balance Sheet

The balance sheet indicates a precarious financial position with high leverage. The debt-to-equity ratio is substantial, suggesting heavy reliance on debt financing, which poses a risk given the industry volatility. However, despite the challenges, a moderate equity ratio shows that the company retains some level of equity relative to its assets. The return on equity is negative due to losses incurred, further emphasizing financial instability. Overall, the balance sheet reflects high financial risk, warranting cautious management.

Cash Flow

The cash flow statement presents concerning trends. The operating cash flow is negative, indicating core operations are not generating cash, and free cash flow has also decreased, showing challenges in maintaining liquidity. The free cash flow growth rate is negative, further exacerbating the liquidity concerns. The ratio of operating cash flow to net income is unfavorable, reflecting operational inefficiencies. These cash flow issues highlight the need for improved cash management and operational efficiency.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	263.80M	122.20M	1.56B	2.14B	1.34B	1.39B
Gross Profit	129.64M	-55.56M	1.29B	1.27B	859.23M	760.32M
EBITDA	-906.82M	-2.02B	-603.09M	-705.34M	348.90M	-261.86M
Net Income	-60.21M	-2.14B	138.16M	-1.06B	-77.63M	-831.86M
Balance Sheet
Total Assets	4.89B	3.54B	5.82B	14.09B	16.01B	14.92B
Cash, Cash Equivalents and Short-Term Investments	443.00M	255.98M	1.04B	1.12B	851.56M	1.07B
Total Debt	2.66B	2.65B	2.47B	8.51B	9.27B	8.53B
Total Liabilities	2.87B	2.91B	3.02B	11.43B	12.29B	11.38B
Stockholders Equity	2.02B	630.54M	2.79B	2.65B	3.71B	3.55B
Cash Flow
Free Cash Flow	0.00	-995.12M	-1.17B	-198.04M	-367.83M	-98.86M
Operating Cash Flow	0.00	-987.04M	-1.15B	-39.52M	-187.78M	-82.90M
Investing Cash Flow	0.00	18.13M	8.69B	-283.06M	-216.19M	6.70M
Financing Cash Flow	0.00	176.43M	-7.17B	294.23M	35.80M	150.65M

Cytori Cell Research Institute, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 914.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3750, the sentiment is Positive. The current price of 914 is above the 20-day moving average (MA) of 911.50, above the 50-day MA of 845.02, and above the 200-day MA of 830.55, indicating a bullish trend. The MACD of 15.97 indicates Positive momentum. The RSI at 60.82 is Neutral, neither overbought nor oversold. The STOCH value of 40.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:3750.

Cytori Cell Research Institute, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
3750	54 Neutral	¥8.16B	55.07		―	-92.12%	-3310.68%
Sector *	47 Neutral	C$212.32M	0.03	-30.33%	3.13%	19.38%	-2.35%
6DW	―	€31.76M	―	-131.16%	―	―	―
30O	―	€45.99M	―	-96.20%	―	―	―
4884	54 Neutral	¥3.40B	―		―	-8.56%	-7.26%
4591	37 Underperform	¥4.89B	―		―	-59.53%	11.70%
4598	28 Underperform	¥7.40B	―		―	―	20.41%